NCT05280314Phase 2Recruiting

Phase II Trial of Neoadjuvant and Adjuvant IO102-IO103 and Pembrolizumab KEYTRUDA® in Patients With Resectable Tumors

Study sponsor: IO Biotech

Primary completion is the date data collection ends for the main study measures, not when results are published.

Primary completion2025-04-30Estimated
Enrollment · participants60Estimated
Source updated2024-03-18Last update listed in the registry record

Changes to this trial

Last 12 months
Filters
Clear filters
No recorded changes are available for this view and time period. Our history may be incomplete; this does not establish that the trial stayed unchanged.

Explore older trial changes

Upgrade to Pro to see the full available history for this trial.

Upgrade to Pro Illustrative preview